Dexamethasone Taw (dexamethasone phosphate)
- Region
- 🇪🇺 EU
- Active substance
- dexamethasone phosphate
- Company
- Taw Pharma (Ireland) Ltd
- Status
- Application withdrawn
- Therapeutic area
- COVID-19 virus infection; Brain Edema; Respiratory Distress Syndrome, Adult; Asthma; Skin Diseases; Autoimmune Diseases; Arthritis; Vomiting; Inflammation; Eye Diseases; Postoperative Nausea and Vomiting
- Application
- EMEA/H/C/005740
- ATC
- H02AB02
- Official record
- www.ema.europa.eu
Indication
Indicated for cerebral oedema, post-traumatic shock-lung syndrome, asthma, skin diseases, autoimmune diseases, rheumatoid arthritis, prophylaxis and treatment of post-operative or cytostatic-induced vomiting, treatment of COVID-19, eye inflammation and infection.
Regulatory milestones
No milestones recorded in the last year.
Follow Dexamethasone Taw
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.